Page last updated: 2024-09-05

erlotinib hydrochloride and Mucositis

erlotinib hydrochloride has been researched along with Mucositis in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hsu, WH; Loong, HH; Mok, TS; Yang, JC	1
de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A	1
Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P	1
Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A	1
Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R	1

Reviews

2 review(s) available for erlotinib hydrochloride and Mucositis

Article	Year
Overview of current systemic management of EGFR-mutant NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 01-01, Volume: 29, Issue:suppl_1 Topics: Acneiform Eruptions; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Molecular Targeted Therapy; Mucositis; Paronychia; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic	2018
[Cutaneous side effects of EGFR inhibitors--appearance and management]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:4 Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines	2010

Article

Year

Overview of current systemic management of EGFR-mutant NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 01-01, Volume: 29, Issue:suppl_1

Topics: Acneiform Eruptions; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Molecular Targeted Therapy; Mucositis; Paronychia; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic

2018

[Cutaneous side effects of EGFR inhibitors--appearance and management].

Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:4

Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines

2010

Trials

2 trial(s) available for erlotinib hydrochloride and Mucositis

Article	Year
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines	2009
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mucositis; Neutropenia; Quinazolines; Taxoids	2011

Article

Year

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.

Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines

2009

Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:12

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mucositis; Neutropenia; Quinazolines; Taxoids

2011

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Mucositis

Article	Year
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clinical lung cancer, 2014, Volume: 15, Issue:4 Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment	2014

Article

Year

management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.

Clinical lung cancer, 2014, Volume: 15, Issue:4

Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment

2014